

Paris, 20 February 2020

Press release Banque Delubac & Cie - Corporate & Investment Bank

Banque Delubac & Cie supports Biophytis, a biotechnology company (listed on Euronext Growth) specialising in neuromuscular diseases, as advisor and overall coordinator of the capital increase of €3.3 million by private placement with American and European investors.



Biophytis is a French biotechnology company listed on Euronext Growth, whose lead drug candidate, Sarconeos (BIO101), is in clinical development in the treatment of neuromuscular diseases including sarcopenia and Duchenne muscular dystrophy (DMD). A second drug candidate, Macuneos (BIO201), is under development for diseases of the retina including age-related macular degeneration (AMD) in its dry form.

Biophytis has successfully completed a capital increase by private placement, totalling 3.3 million euros, subscribed by European and American investors.

The purpose of the capital increase is to finance, in particular, the continued preparation of the MYODA clinical study in Duchenne muscular dystrophy, knowing that Sarconeos (BIO101), its most advanced drug candidate for the treatment of neuromuscular diseases, received the IND status (Investigational New Drug) from the US Food and Drug Administration (FDA) in December 2019.

The gross final amount of the capital increase (issue premium included) amounts to 3,346,399.17 euros and results in the issue of 12,394,071 new shares, i.e. 31.6% of the capital after the company's capital increase. The subscription price was set at 0.27 euro per new share, i.e. a discount of 29.5% based on the weighted average of the Biophytis share price over the last 10 trading sessions preceding the 12 February 2020.

Stanislas Veillet, President and CEO of Biophytis, declares: *'We are pleased to announce the success of the 3.3 million euro capital increase. It allows Biophytis to strengthen its funding structure, in particular in order to continue preparations for the Myoda clinical study in Duchenne muscular dystrophy. Indeed, Sarconeos (BIO101) received the IND status from the FDA in December. I thank our loyal investors who have followed us for years and who have not hesitated to invest again in Biophytis.'*

Christine Lambert-Goué, Corporate & Investment Bank Director of Banque Delubac & Cie declares: *'We are very happy to have supported Biophytis in its capital increase. This operation strengthens its equity capital and supplements the financing methods already in place. It has generated strong demand from leading US and European investors. This is a very positive signal and a great sign of confidence for the development prospects of Biophytis.'*

Banque Delubac & Cie acted as advisor and overall coordinator of the operation, alongside the American bank H.C. Wainwright & Co., Exclusive Placement Agent for the United States.

About BIOPHYTIS:

Biophytis SA is a clinical-stage biotechnology company specialising in the development of drug candidates that slow down degenerative processes and improve functional capacities in patients with age-related diseases, particularly neuromuscular diseases.

Sarconeos (BIO101), its lead drug candidate, is an orally administered small molecule, currently in clinical phase 2b in sarcopenia (SARA-INT) in the United States and Europe. A paediatric formulation of Sarconeos (BIO101) is under development for the treatment of Duchenne muscular dystrophy (DMD) for which the company received IND status by the U.S. Food and Drug Administration (FDA) in December 2019.

The company is based in Paris, France and Cambridge, Massachusetts. The company's ordinary shares are listed on the Euronext Growth Paris market (Ticker: ALBPS -ISIN: FR0012816825).

More information on: www.biophytis.com

About Banque Delubac & Cie:

Created in 1924, Banque Delubac & Cie, is an independent financial institution offering specialised banking and financial services. With over 200 employees, it is present in Paris, Lyon, Toulouse, Valence and Le Cheylard (historic head office, located in Ardèche).

Its Corporate & Investment Bank department has been developing for 10 years advisory services for mergers and acquisitions, engineering and financial operations for listed and unlisted companies.

More information on: www.delubac.com

Banque Delubac & Cie Contacts:

Mickaël Hazout - Managing Director, Corporate & Investment Bank - mickael.hazout@delubac.fr

Christine Lambert-Goué – Director, Corporate & Investment Bank - christine.lambertgoue@delubac.fr

Arthur Libier – Analyst, Corporate & Investment Bank - arthur.libier@delubac.fr